Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE)
Background: Lassa Fever (LF), is a severe viral disease prevalent in Western Africa. It is classified as a priority disease by the World Health Organization (WHO). Ribavirin is the recommended therapy despite weak evidence of its efficacy. Promising therapeutic agents are becoming available for eval...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2020
|
| _version_ | 1826260582969376768 |
|---|---|
| author | Duvignaud, A Jaspard, M Etafo, IC Serra, B Abejegah, C Gabillard, D Doutchi, M Alabi, JF Adedokun, MA Akinpelu, AO Oyegunle, OO Etafo, J Dede, AO Onyechi, MN Ireneh, MU Gbenga-Ayeni, O Fadiminiyi, KG Ehigbor, PI Ouattara, E Levy-Marchal, C Karcher, S N'guessan-Koffi, L Ahyi, I Amani, E Diabaté, M Siloué, B Schaeffer, J Augier, A Ogbaini-Emovon, E Salam, AP Horby, P Ahmed, LA Günther, S Adedosu, AN Anglaret, X Ayodeji, OO Malvy, D |
| author_facet | Duvignaud, A Jaspard, M Etafo, IC Serra, B Abejegah, C Gabillard, D Doutchi, M Alabi, JF Adedokun, MA Akinpelu, AO Oyegunle, OO Etafo, J Dede, AO Onyechi, MN Ireneh, MU Gbenga-Ayeni, O Fadiminiyi, KG Ehigbor, PI Ouattara, E Levy-Marchal, C Karcher, S N'guessan-Koffi, L Ahyi, I Amani, E Diabaté, M Siloué, B Schaeffer, J Augier, A Ogbaini-Emovon, E Salam, AP Horby, P Ahmed, LA Günther, S Adedosu, AN Anglaret, X Ayodeji, OO Malvy, D |
| author_sort | Duvignaud, A |
| collection | OXFORD |
| description | Background: Lassa Fever (LF), is a severe viral disease prevalent in Western Africa. It is classified as a priority
disease by the World Health Organization (WHO). Ribavirin is the recommended therapy despite weak evidence
of its efficacy. Promising therapeutic agents are becoming available for evaluation in human. Before launching
therapeutic trials, we need data on the evolution of the disease under the best possible conditions of care.
Methods: We have initiated a prospective study in Nigeria to better understand the clinical course and prognostic
factors of LF while implementing high quality standardized care. Inclusion criteria are: suspected or confirmed
LF and informed consent. Participants are followed 60 days from admission and receive free of charge standardized supportive care and biological monitoring, as well as intravenous ribavirin for those with confirmed LF.
Data are collected using standardized case report forms (CRF). Primary and secondary outcomes are fatality and
severe morbidity, with special focus on acute kidney dysfunction and pregnancy complications. Factors associated with outcomes will be investigated.
Results: The cohort is planned for 3 years. Inclusions started in April 2018 at the Federal Medical Center Owo in
Ondo State. A second site will open in Nigeria in 2020 and discussions are underway to open a site in Benin. 150
to 200 new participants are expected per year.
Conclusions: This cohort will: provide evidence to standardize LF case management; provide key inputs to design
future clinical trials of novel therapeutics; and establish clinical research teams capable of conducting such trials
in LF-endemic areas. |
| first_indexed | 2024-03-06T19:07:58Z |
| format | Journal article |
| id | oxford-uuid:15cfb81a-a805-47bb-97bc-5323999ae2b6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:07:58Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:15cfb81a-a805-47bb-97bc-5323999ae2b62022-03-26T10:27:39ZLassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:15cfb81a-a805-47bb-97bc-5323999ae2b6EnglishSymplectic ElementsElsevier2020Duvignaud, AJaspard, MEtafo, ICSerra, BAbejegah, CGabillard, DDoutchi, MAlabi, JFAdedokun, MAAkinpelu, AOOyegunle, OOEtafo, JDede, AOOnyechi, MNIreneh, MUGbenga-Ayeni, OFadiminiyi, KGEhigbor, PIOuattara, ELevy-Marchal, CKarcher, SN'guessan-Koffi, LAhyi, IAmani, EDiabaté, MSiloué, BSchaeffer, JAugier, AOgbaini-Emovon, ESalam, APHorby, PAhmed, LAGünther, SAdedosu, ANAnglaret, XAyodeji, OOMalvy, DBackground: Lassa Fever (LF), is a severe viral disease prevalent in Western Africa. It is classified as a priority disease by the World Health Organization (WHO). Ribavirin is the recommended therapy despite weak evidence of its efficacy. Promising therapeutic agents are becoming available for evaluation in human. Before launching therapeutic trials, we need data on the evolution of the disease under the best possible conditions of care. Methods: We have initiated a prospective study in Nigeria to better understand the clinical course and prognostic factors of LF while implementing high quality standardized care. Inclusion criteria are: suspected or confirmed LF and informed consent. Participants are followed 60 days from admission and receive free of charge standardized supportive care and biological monitoring, as well as intravenous ribavirin for those with confirmed LF. Data are collected using standardized case report forms (CRF). Primary and secondary outcomes are fatality and severe morbidity, with special focus on acute kidney dysfunction and pregnancy complications. Factors associated with outcomes will be investigated. Results: The cohort is planned for 3 years. Inclusions started in April 2018 at the Federal Medical Center Owo in Ondo State. A second site will open in Nigeria in 2020 and discussions are underway to open a site in Benin. 150 to 200 new participants are expected per year. Conclusions: This cohort will: provide evidence to standardize LF case management; provide key inputs to design future clinical trials of novel therapeutics; and establish clinical research teams capable of conducting such trials in LF-endemic areas. |
| spellingShingle | Duvignaud, A Jaspard, M Etafo, IC Serra, B Abejegah, C Gabillard, D Doutchi, M Alabi, JF Adedokun, MA Akinpelu, AO Oyegunle, OO Etafo, J Dede, AO Onyechi, MN Ireneh, MU Gbenga-Ayeni, O Fadiminiyi, KG Ehigbor, PI Ouattara, E Levy-Marchal, C Karcher, S N'guessan-Koffi, L Ahyi, I Amani, E Diabaté, M Siloué, B Schaeffer, J Augier, A Ogbaini-Emovon, E Salam, AP Horby, P Ahmed, LA Günther, S Adedosu, AN Anglaret, X Ayodeji, OO Malvy, D Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE) |
| title | Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE) |
| title_full | Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE) |
| title_fullStr | Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE) |
| title_full_unstemmed | Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE) |
| title_short | Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE) |
| title_sort | lassa fever clinical course and setting a standard of care for future randomized trials a protocol for a cohort study of lassa infected patients in nigeria lascope |
| work_keys_str_mv | AT duvignauda lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT jaspardm lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT etafoic lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT serrab lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT abejegahc lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT gabillardd lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT doutchim lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT alabijf lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT adedokunma lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT akinpeluao lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT oyegunleoo lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT etafoj lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT dedeao lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT onyechimn lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT irenehmu lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT gbengaayenio lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT fadiminiyikg lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT ehigborpi lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT ouattarae lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT levymarchalc lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT karchers lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT nguessankoffil lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT ahyii lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT amanie lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT diabatem lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT siloueb lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT schaefferj lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT augiera lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT ogbainiemovone lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT salamap lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT horbyp lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT ahmedla lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT gunthers lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT adedosuan lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT anglaretx lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT ayodejioo lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope AT malvyd lassafeverclinicalcourseandsettingastandardofcareforfuturerandomizedtrialsaprotocolforacohortstudyoflassainfectedpatientsinnigerialascope |